TABLE 1.

Frequency of JAK2 mutations and JAK2 rearrangements within Ph-like ALL. Prevalence of CRLF2r/JAK mutant and JAK2r subtypes of Ph-like ALL compared with Ph-like ALL cases without CRLF2 overexpression.

Clinical trial	Age (years)	Total (N)	Non-CRLF2	CRLF2r JAK WT	CRLF2r JAK mutant	JAK2r	References
AALL0232	1–18	31	8	10	12	1	Loh et al. (2013)
Multiple trials*							Roberts et al., 2014a
	1–15 (SR)	33	25	5	3	0
	1–15 (HR)	108	57	19	26	6
	16–20	77	27	14	32	4
	21–39	46	15	17	7	7
GMALL	15–65	16	5	5	6	N/A**	Herold et al. (2017)
University Pennsylvania							Tasian et al., 2017a
	18–39	7	2	3	2	0
	40–88	11	2	4	5	0
Multiple trials
	21–39	96	41	35	14	6	Roberts et al., 2017a
	40–59	62	27	24	5	6
	60–86	36	13	15	6	2
St. Jude Total XV	1–18	40	29	5	6	0	Roberts et al., 2014b

*Multiple trials include cohorts from St. Jude’s Children’s Research Hospital, the Children’s Oncology Group (COG), the Eastern Cooperative Oncology Group (ECOG), M.D., Anderson Cancer Center (MDACC), and the Alliance for Clinical Trials in Oncology (Cancer and Leukemia Group B, CALGB).

**Data not available.